O-异丙基乙酰氨基苯 | 7146-61-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: O-异丙基乙酰氨基苯
• 英文名称: 4-Isopropoxyacetanilide
• 英文别名: N-(4-isopropoxyphenyl)acetamide；acetic acid-(4-isopropoxy-anilide)；Essigsaeure-(4-isopropoxy-anilid)；Essigsaeure-(4-isopropyloxy-anilid)；N-(4-propan-2-yloxyphenyl)acetamide
• CAS: 7146-61-4
• 化学式: C₁₁H₁₅NO₂
• mdl: MFCD00463571
• 分子量: 193.246
• InChiKey: QCSNJTIWCIMFFY-UHFFFAOYSA-N

物化性质

• 熔点：
  131 °C
• 沸点：
  358.3±25.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

O-异丙基对乙酰氨基酚已知的人类代谢物包括对乙酰氨基酚和N-(4-甲氧基苯基)甲酰胺。

O-isopropyl acetaminophen has known human metabolites that include acetaminophen and N-(4-Methoxyphenyl)formamide.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  O-异丙基乙酰氨基苯 在 copper(l) iodide 、 四(三苯基膦)钯 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 45.5h， 生成 3-[(3-formyl-6-isopropoxy-2-quinolinyl)ethynyl]-N-[2-(4-morpholinyl)ethyl]benzamide
  参考文献：
  名称：

  Overcoming Compound Fluorescence in the FLiK Screening Assay with Red-Shifted Fluorophores

  摘要：

  In the attempt to discover novel chemical scaffolds that can modulate the activity of disease-associated enzymes, such as kinases, biochemical assays are usually deployed in high-throughput screenings. First-line assays, such as activity-based assays, often rely on fluorescent molecules by measuring a change in the total emission intensity, polarization state, or energy transfer to another fluorescent molecule. However, under certain conditions, intrinsic compound fluorescence can lead to difficult data analysis and to false-positive, as well as false-negative, hits. We have reported previously on a powerful direct binding assay called fluorescent labels in kinases ('FLiK'), which enables a sensitive measurement of conformational changes in kinases upon ligand binding. In this assay system, changes in the emission spectrum of the fluorophore acrylodan, induced by the binding of a ligand, are translated into a robust assay readout. However, under the excitation conditions of acrylodan, intrinsic compound fluorescence derived from highly conjugated compounds complicates data analysis. We therefore optimized this method by identifying novel fluorophores that excite in the far red, thereby avoiding compound fluorescence. With this advancement, even rigid compounds with multiple pi-conjugated ring systems can now be measured reliably. This study was performed on three different kinase constructs with three different labeling sites, each undergoing distinct conformational changes upon ligand binding. It may therefore serve as a guideline for the establishment of novel fluorescence-based detection assays.

  DOI：

  10.1021/ja403074j
• 作为产物：
  描述：

  2-碘代丙烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 作用下， 生成 O-异丙基乙酰氨基苯
  参考文献：
  名称：

  Isopropyl ether of para-acetyl amino phenol

  摘要：

  公开号：

  US01793030A1

文献信息

• Über lokalanästhetisch wirksame Substitutionsderivate des Diäthylamino-acyl-anilids
  作者：J. Büchi、G. Lauener、L. Ragaz、H. Böniger、R. Lieberherr

  DOI：10.1002/hlca.19510340131

  日期：——

  hergestellt und auf ihre pharmakologischen Wirkungen untersucht. Die hier beschriebenen Diäthylamino-acylaminophenol-alkyläther und Diäthylamino-acetylamino-toluol-alkyläther zeigen ähnliche Zusammenhänge zwischen Konstitution und Wirkung, wie sie schon bei andern Stoffgruppen beobachtet worden sind. Es wurde zudem auf den eigenartigen Einfluss der Einführung von Methylgruppen in den Phenolkern des p-(Diä

  Es wurden verschiedene同系物Reihen vonXylocain-ähnlichenLokalanästhetikahergestellt和auf i pharmakologischen Wirkungen untersucht。乙二氨基氨基-乙酰氨基苯酚-烷基醚和二乙氨基-乙酰氨基-甲苯基-烷基醚的合成和Wirkung的二元氨基-乙酰氨基-乙酰氨基-苯酚烷基酯和Wirkung的二氨基氨基-乙酰氨基-乙酰氨基酚烷基酯。在对苯二甲酰二乙酰氨基乙酰氨基苯酚烷基酚的合成中使用了甲基丙烯酸丁酯（Einfluss derEinführungvonEinführungvon Methylgruppen）。Dabei konnte beim二氨基氨基乙酰氨基-二甲苯醇-烷基酯，D Kombination der Strukturen des Xylocains和des Pacetacetins，Eine
• REMEDIES FOR NEUROPATHIC PAIN
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1182193A1

  公开（公告）日：2002-02-27

  The present invention relates to a compound represented by Formula (I) below: (wherein A represents, for example, phenyl group substituted by R1 and R2, or an unsubstituted furyl group or an unsubstitued thienyl group; R1 represents, for example, hydrogen atom, fluorine atom, chlorine atom, trifluoromethyl group, nitro group, cyano group or methyl group while R2 represents, for example, hydrogen atom; R3 represents, for example, hydrogen atom or methyl group; R4 represents, for example, hydrogen atom or methyl group; R5 represents ethoxy group or isopropoxy group; X represents group: -CH(OH)- or methylene group; and Z represents, for example, a single bond or methylene group unsubstituted or substituted by hydroxyl group), and its salts, and medicinal compositions containing, as their active ingredient, the above compound or its salts. The compound of this invention, which is orally applicable, is highly effective for treating neuroapthic pain while presenting with fewer side-effects than do the conventional analgesics.

  本发明涉及一种化合物，其由以下通式(I)表示：(其中A代表例如被R1和R2取代的苯基，或未被取代的呋喃基或未被取代的噻吩基；R1代表例如氢原子、氟原子、氯原子、三氟甲基、硝基、氰基或甲基，而R2代表例如氢原子；R3代表例如氢原子或甲基；R4代表例如氢原子或甲基；R5代表乙氧基或异丙氧基；X代表基团：-CH(OH)-或亚甲基；Z代表例如单键或未被取代或被羟基取代的亚甲基)，及其盐，以及含有上述化合物或其盐作为活性成分的药物组合物。本发明的化合物可经口给药，对治疗神经痛性疼痛具有高度有效性，且相比传统镇痛药副作用更少。
• Agents for treating neuropathic pain
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20020049229A1

  公开（公告）日：2002-04-25

  The present invention relates to a compound represented by Formula (I) below: 1 (wherein A represents, for example, phenyl group substituted by R 1 and R 2 , or an unsubstituted furyl group or an unsubstitued thienyl group; R 1 represents, for example, hydrogen atom, fluorine atom, chlorine atom, trifluoromethyl group, nitro group, cyano group or methyl group while R 2 represents, for example, hydrogen atom; R 3 represents, for example, hydrogen atom or methyl group; R 4 represents, for example, hydrogen atom or methyl group; R 5 represents ethoxy group or isopropoxy group; X represents group: —CH(OH)— or methylene group; and Z represents, for example, a single bond or methylene group unsubstituted or substituted by hydroxyl group), and its salts, and medicinal compositions containing, as their active ingredient, the above compound or its salts. The compound of this invention, which is orally applicable, is highly effective for treating neuroapthic pain while presenting with fewer side-effects than do the conventional analgesics.

  本发明涉及一种化合物，其由下面的式(I)表示：1（其中A表示例如由R1和R2取代的苯基，或未取代的呋喃基或未取代的噻吩基；R1表示例如氢原子、氟原子、氯原子、三氟甲基、硝基、氰基或甲基，而R2表示例如氢原子；R3表示例如氢原子或甲基；R4表示例如氢原子或甲基；R5表示乙氧基或异丙氧基；X表示基团：—CH(OH)—或亚甲基；Z表示例如单键或未取代或由羟基取代的亚甲基），及其盐，以及含有上述化合物或其盐作为活性成分的药物组合物。本发明的化合物可口服使用，在治疗神经性疼痛方面具有高效率，同时相比传统镇痛药副作用更少。
• Direct acetoxylation and etherification of anilides using phenyliodine bis(trifluoroacetate)
  作者：Huan Liu、Xuemin Wang、Yonghong Gu

  DOI：10.1039/c0ob00749h

  日期：——

  Treatment of various anilides with 1.5 equiv. of phenyliodine bis(trifluoroacetate) (PIFA) and 1.0 equiv. of BF3·OEt2 in AcOH at room temperature afforded the corresponding para-acetoxylated products with high regioselectivity. In addition, this reaction could be expanded to the etherification of anilides. In the presence of 2.0 equiv. of PIFA and 2.0 equiv. of BF3·OEt2, the reaction of anilides with alcohols provided the corresponding para-etherified products in good yields.

  用1.5当量的苯碘双(trifluoroacetate)（PIFA）和1.0当量的BF3·OEt2在醋酸中室温处理各种酰胺，得到了相应的对位乙氧基化产物，且具有高区位选择性。此外，该反应可以扩展到酰胺的醚化反应。在使用2.0当量的PIFA和2.0当量的BF3·OEt2的条件下，酰胺与醇的反应提供了良产率的相应对位醚化产物。
• [EN] SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN<br/>[FR] AGENTS DE DÉGRADATION À PETITES MOLÉCULES DE PROTÉINE SHP2
  申请人：THE REGENTS OF THE UNIV OFMICHIGAN

  公开号：WO2021236775A1

  公开（公告）日：2021-11-25

  The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein R1, R3, L, Y, and B1 are as defined in the specification. Compounds having Formula I are SHP2 protein degraders useful for the treatment of cancer and other diseases.

  本公开提供由式I表示的化合物及其盐或溶剂合物，其中R1、R3、L、Y和B1如规范中所定义。具有式I的化合物是对癌症和其他疾病治疗有用的SHP2蛋白降解剂。